In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC)
chemo-and targeted therapy are used. Response rates after platinum-based chemotherapy …

Background Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now
play a vital role in patient care of this neoplasm. The authors focused on the impact of …

Central nervous system (CNS) progression is frequently detected in patients with favorable
initial responses to first-generation epidermal growth factor receptor-tyrosine kinase …

Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …

The brain is one of the most common sites for lung adenocarcinoma metastasis, which are
found in almost 20-30% of patients with the disease (1). These patients have poor median …

Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …

Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery
(SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers …

Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …

Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …

Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …